Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus TACE for Unresectable HCC
NCT00576056Phase 2Terminated
- Sponsor
- University of Pittsburgh
- Start
- Jan 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by University of Pittsburgh. Primary endpoint: Progression-Free Survival at 24 months. Started Jan 2008; status: terminated.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00576056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00576056.